Health Blueprint

Back to Longevity News

News summary

Arvinas to present new Phase 1 Parkinson’s drug data at global conference

Source: Longevity Technology • Published: 02 Oct 2026, 09:36

Summarized by Masters of Longevity from Longevity Technology.

ARV-102 and related PROTAC research take center stage in a conference preview describing upcoming biomarker and early clinical data presentations.

Arvinas to present new Phase 1 Parkinson’s drug data at global conference
Key Takeaways
  • Arvinas will present novel biomarker data from a Phase 1 trial of ARV-102 at the 2026 Parkinson's congress.
  • ARV-102 is an orally bioavailable PROTAC designed to cross the blood-brain barrier and degrade LRRK2.
  • Arvinas highlighted a broader PROTAC pipeline that includes ARV-393, ARV-027, ARV-6723 and ARV-806.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.